1
Shenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen–Hong Kong Institute of Brain Science, Shenzhen Institute of
Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong Province, China;
2
CAS Key Laboratory of Brain Connectome and Manipulation,
Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong Province,
China;
3
Guangdong Provincial Key Laboratory of Brain Connectome and Behavior, the Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute
of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong Province, China;
4
University of Chinese of Academy of Sciences, Beijing, China; 5
Faculty of Life and Health Sciences, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong Province, China
Online:2025-06-15
Published:2024-11-12
Contact:
Jie Tu, PhD, jie.tu@siat.ac.cn; Qian Xiao, PhD, qian.xiao@siat.ac.cn
Supported by:
This study was supported by the National Natural Science Foundation of China, Nos. 32371070 (to JT), 31761163005 (to JT), 32100824 (to QX),
the Shenzhen Science and Technology Program, Nos. RCBS20210609104606024 (to QX), JCY20210324101813035 (to DL); the Guangdong Provincial
Key S&T Program, No. 2018B030336001 (to JT); the Key Basic Research Program of Shenzhen Science and Technology Innovation Commission, Nos.
JCYJ20200109115405930 (to JT), JCYJ20220818101615033 (to DL), JCYJ20210324115811031 (to QX), JCYJ20200109150717745 (to QX); Shenzhen Key
Laboratory of Neuroimmunomodulation for Neurological Diseases, No. ZDSYS20220304163558001 (to JT); Guangdong Provincial Key Laboratory of Brain
Connectome and Behavior, No. 2023B1212060055 (to JT); and the China Postdoctoral Science Foundation, No. 2021M693298 (to QX).